ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Two biosimilars get U.S. panel’s nod

by Michael McCoy
July 18, 2016 | APPEARED IN VOLUME 94, ISSUE 29

An FDA advisory panel voted unanimously last week to recommend that the agency approve biosimilar versions of two multi-billion-dollar-selling arthritis drugs. FDA often accepts such panels’ recommendations. The panel voted 20-0 in support of Sandoz’s version of Enbrel, an Amgen drug that is used to treat arthritis and psoriasis. The panel also voted 26-0 in favor of approving Amgen’s version of the AbbVie arthritis drug Humira. In the latter case, AbbVie claims to have patents that protect Humira from competition until at least 2022.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment